The influence of secreted factors and extracellular vesicles in ovarian cancer metastasis.

Publisher: Pergamon/Elsevier Country of Publication: England NLM ID: 101195509 Publication Model: eCollection Cited Medium: Print ISSN: 1359-6349 (Print) Linking ISSN: 13596349 NLM ISO Abbreviation: EJC Suppl Subsets: PubMed not MEDLINE

Original Publication: Oxford, UK : Pergamon/Elsevier, 2003-

Ovarian cancer cells mainly metastasise within the peritoneal cavity, the lethal consequence of tumour progression in this cancer type. Classically, changes in tumour cells, such as epithelial to mesenchymal transition, involve the down-regulatinon of E-cadherin, activation of extracellular proteases and integrin-mediated adhesion. However, our current understanding of ovarian tumour progression suggests the implication of both intrinsic and extrinsic factors. It has been proposed that ovarian cancer metastases are a consequence of the crosstalk between cancer cells and the tumour microenvironment by soluble factors and extracellular vesicles. Characterisation of the alterations in both the tumour cells and the surrounding microenvironment has emerged as a new research field to understand ovarian cancer metastasis. In this mini review, we will summarise the most recent findings, focusing our attention on the role of secreted factors and extracellular vesicles in ovarian cancer metastasis.
Competing Interests: The author declare no conflict of interest.
(© 2020 The Authors.)

Nat Commun. 2016 Mar 29;7:11150. (PMID: 27021436)
J Clin Invest. 1995 May;95(5):2391-6. (PMID: 7738202)
Cancer. 1997 Oct 15;80(8):1457-63. (PMID: 9338470)
PLoS One. 2010 Jul 22;5(7):e11469. (PMID: 20661468)
J Clin Invest. 2008 Apr;118(4):1367-79. (PMID: 18340378)
Biomed Res Int. 2015;2015:701390. (PMID: 26583126)
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):. (PMID: 29158318)
J Proteomics. 2013 Mar 27;80:171-82. (PMID: 23333927)
Trends Cancer. 2015 Sep;1(1):76-91. (PMID: 28741564)
J Clin Invest. 2014 Oct;124(10):4614-28. (PMID: 25202979)
Cancer Lett. 2017 May 1;393:60-67. (PMID: 28216373)
Gynecol Obstet (Sunnyvale). 2013 Apr 29;Suppl 4:3. (PMID: 24466501)
BMC Genomics. 2017 Mar 21;18(1):243. (PMID: 28327095)
J Mol Med (Berl). 2015 Nov;93(11):1171-2. (PMID: 26518203)
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):. (PMID: 29158314)
Oncol Rep. 2018 May;39(5):2081-2090. (PMID: 29565447)
J Natl Cancer Inst. 2015 Jul 06;107(9):. (PMID: 26150590)
Oncotarget. 2015 Aug 28;6(25):21100-19. (PMID: 26053184)
Tumour Biol. 2016 Apr;37(4):5031-7. (PMID: 26541760)
Am J Pathol. 2013 Aug;183(2):576-91. (PMID: 23885715)
Nat Commun. 2019 Jul 5;10(1):3000. (PMID: 31278254)
PLoS One. 2015 Feb 06;10(2):e0118080. (PMID: 25658637)
Cancer Res. 2008 Feb 15;68(4):1100-9. (PMID: 18281485)
Nat Med. 2011 Oct 30;17(11):1498-503. (PMID: 22037646)
Cancer Immunol Res. 2015 Nov;3(11):1269-78. (PMID: 26112921)
Nat Rev Cancer. 2003 Jun;3(6):453-8. (PMID: 12778135)
Gynecol Oncol. 2011 Nov;123(2):379-86. (PMID: 21903249)
Am J Pathol. 2001 Dec;159(6):2071-80. (PMID: 11733357)
Oncotarget. 2017 Oct 6;8(56):96035-96047. (PMID: 29221185)
Gynecol Oncol. 2010 May;117(2):366-72. (PMID: 20144842)
J Immunol. 2005 Jul 15;175(2):1197-205. (PMID: 16002723)
Cell. 2016 Mar 10;164(6):1226-1232. (PMID: 26967288)
Cancer Metastasis Rev. 2014 Mar;33(1):17-39. (PMID: 24357056)
Cancer Res. 2013 Aug 15;73(16):5016-28. (PMID: 23824740)
Cancer Res. 2009 Feb 15;69(4):1469-76. (PMID: 19208843)
Nature. 2016 Mar 24;531(7595):513-7. (PMID: 26982733)
J Clin Invest. 2016 Nov 1;126(11):4157-4173. (PMID: 27721235)
Endocr Relat Cancer. 2013 Mar 22;20(2):251-62. (PMID: 23404857)
Cancer Metastasis Rev. 1989 Aug;8(2):98-101. (PMID: 2673568)
Cell Physiol Biochem. 2017;43(5):1893-1906. (PMID: 29055949)
Nature. 2015 Nov 19;527(7578):329-35. (PMID: 26524530)
J Cell Biol. 2013 Feb 18;200(4):373-83. (PMID: 23420871)
Int J Epidemiol. 2016 Jun;45(3):884-95. (PMID: 27401727)
Am J Pathol. 2006 Nov;169(5):1739-52. (PMID: 17071597)
Cancer Res. 2008 Apr 1;68(7):2329-39. (PMID: 18381440)
Br J Cancer. 2017 Oct 24;117(9):1371-1382. (PMID: 28898232)
Nat Rev Cancer. 2009 Apr;9(4):239-52. (PMID: 19279573)
Nat Commun. 2014 Oct 03;5:5092. (PMID: 25277212)
Nature. 2005 Dec 8;438(7069):820-7. (PMID: 16341007)
Nat Rev Clin Oncol. 2019 Feb;16(2):75-76. (PMID: 30568177)
Proteomes. 2019 Apr 11;7(2):. (PMID: 30979041)
Int Immunopharmacol. 2016 Nov;40:184-195. (PMID: 27608303)
Carcinogenesis. 2020 Apr 22;41(2):182-193. (PMID: 31046126)
PLoS One. 2013 Dec 02;8(12):e81859. (PMID: 24312594)
Am J Physiol Cell Physiol. 2015 Oct 1;309(7):C444-56. (PMID: 26224579)
Nat Med. 2004 Sep;10(9):942-9. (PMID: 15322536)
Int J Gynecol Cancer. 2014 May;24(4):670-5. (PMID: 24614825)
Gynecol Oncol. 1999 Jun;73(3):362-7. (PMID: 10366461)
Oncotarget. 2015 Apr 10;6(10):7713-26. (PMID: 25797257)
Br J Cancer. 2005 Jan 31;92(2):305-11. (PMID: 15655551)
Cancer Lett. 2015 Oct 10;367(1):26-33. (PMID: 26189430)
J Immunol. 2018 Dec 15;201(12):3750-3758. (PMID: 30446565)
Nat Cell Biol. 2007 Jun;9(6):654-9. (PMID: 17486113)
Br J Cancer. 2004 Apr 5;90(7):1437-42. (PMID: 15054468)
Clin Cancer Res. 2008 Jun 1;14(11):3372-9. (PMID: 18519766)
J Exp Med. 2019 Mar 4;216(3):688-703. (PMID: 30710055)
Cancer Cell. 2016 Dec 12;30(6):836-848. (PMID: 27960084)
Cancer Res. 2015 Dec 1;75(23):5046-57. (PMID: 26573796)
Sci Rep. 2016 Dec 08;6:38498. (PMID: 27929108)
Oncotarget. 2016 Dec 27;7(52):86999-87015. (PMID: 27894104)
Mol Cancer. 2019 Mar 1;18(1):32. (PMID: 30823926)
Int J Cancer. 1989 Nov 15;44(5):795-801. (PMID: 2583859)
Cancer Res. 2016 Dec 15;76(24):7194-7207. (PMID: 27742688)
Mol Cancer Res. 2017 Jan;15(1):78-92. (PMID: 27758876)
Front Oncol. 2017 Feb 22;7:24. (PMID: 28275576)
J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42. (PMID: 12165638)
Nat Med. 2012 Jun;18(6):883-91. (PMID: 22635005)
Oncogene. 2011 Mar 31;30(13):1566-76. (PMID: 21119598)
Cancer Res. 2004 Oct 1;64(19):7045-9. (PMID: 15466198)
Clin Exp Metastasis. 2012 Oct;29(7):737-46. (PMID: 22669542)
Am J Pathol. 2012 Nov;181(5):1573-84. (PMID: 23022210)
Curr Pharm Des. 2012;18(25):3816-27. (PMID: 22591418)
Cancer Res. 2007 Aug 1;67(15):7194-202. (PMID: 17671187)
Cell Mol Neurobiol. 2016 Apr;36(3):301-12. (PMID: 27053351)
Gynecol Oncol. 2007 Dec;107(3):563-71. (PMID: 17900673)
EMBO Mol Med. 2014 Sep 11;6(10):1279-93. (PMID: 25214461)
J Extracell Vesicles. 2017 Jul 3;6(1):1340746. (PMID: 28717426)
Nat Rev Cancer. 2017 May;17(5):302-317. (PMID: 28303905)
J Ovarian Res. 2014 Apr 22;7:41. (PMID: 24834130)
Cancer Res. 2013 Apr 15;73(8):2480-92. (PMID: 23436796)
Nat Rev Cancer. 2009 Apr;9(4):285-93. (PMID: 19308068)
Cytokine. 2012 Aug;59(2):228-36. (PMID: 22595649)
Oncogene. 2017 Jun 15;36(24):3384-3396. (PMID: 28114283)
Cell Mol Life Sci. 2018 Feb;75(3):509-525. (PMID: 28956065)
Cancer Res. 2007 Jun 15;67(12):5708-16. (PMID: 17575137)
J Exp Med. 2006 Apr 17;203(4):871-81. (PMID: 16606666)
Gastroenterol Res Pract. 2012;2012:541842. (PMID: 22888339)
Nat Cell Biol. 2015 Jun;17(6):816-26. (PMID: 25985394)

Keywords: Cancer; Exosomes; Extracellular vesicles; Metastasis

Date Created: 20201126 Latest Revision: 20201127

20240513

PMC7573474

10.1016/j.ejcsup.2019.09.001

33240441